Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk

Dow Jones

10/27

0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, HSBC analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. "We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma," the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com)

(END) Dow Jones Newswires

October 27, 2025 03:19 ET (07:19 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2578692206"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578692206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578692206?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 15:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578692206","market":"sg","top_or_hot":-1,"title":"Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 03:19 ET (07:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-27 15:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 03:19 ET (07:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0455707207.USD","symbol_name":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578692206","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578692206","pubTimestamp":1761549540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, HSBC analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","HSHD.SI":"HSBC HK SDR 5to1","BK4207":"综合性银行","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","BK1610":"ETF&股票定投概念","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1601":"香港本地股","BK4585":"ETF&股票定投概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","00005":"汇丰控股","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","BK1583":"高瓴概念","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","HSBC":"汇丰","BK1231":"综合性银行","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","01801":"信达生物","BK4521":"英国银行股","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1572":"香港银行股","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1589":"北水核心资产","BK4588":"碎股","HSBA.UK":"汇丰控股有限公司","03143":"华夏香港银行股"},"translate_title":"信达生物通过武田癌症药物合作伙伴关系实现全球增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00005":0.7,"01801":0.9,"03143":0.6,"HSBA.UK":0.6,"HSBC":0.9,"HSHD.SI":0.6},"content_text":"0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, HSBC analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 27, 2025 03:19 ET (07:19 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}